The unambiguous demonstration of opioid receptor types, and their endogenous ligands, the endorphins, together with a diverse range of synthetic ligands, has created exciting opportunities for research highly relevant to drug abuse. One major objective of this project is to continue the process of defining new opioid receptor subtypes. This process is optimally accomplished by synergistic collaborations with medicinal chemists to develop (a) selective high affinity ligands for each subtype (b) irreversible ligands with receptor subtype specificity and (c) enantiomeric pairs of these ligands for detection of receptor mediated effects. Delta receptor antagonists attenuate alcohol consumption, block morphine tolerance and dependence and decrease cocaine- reinforcement. . Recent work has further delineated two subtypes of the delta binding site, and provided new information about subtypes of the delta-cx subtype. The determination of delta receptor subtypes may lead to new medicines for the treatment of alcoholism and drug addiction. Collaborative efforts with Dr. Rice's lab have led to the identification and biological evaluation of highly selective nonpeptide delta agonists. Other studies with the cloned opioid receptor indicated that potency, efficacy and intrinsic efficacy may be mediated by different binding domains. Converging lines of investigation suggest that kappa receptor antagonists may be useful for the treatment of depression, anxiety, psychosis and craving. Previous demonstrated up to four subtypes of kappa opioid receptors in rat, guinea pig and human brain, suggesting that it may be possible to develop kappa agonists devoid of psychotomimetic side effects. More recent studies using the novel radioligand [125I]IOXY showed that kappa2 receptors are up-regulated by cocaine in fatal overdose victims. The notion that dysfunction of the CNS opioid receptor/endorphin system contributes to drug abuse was tested in an open-label study of buprenorphine combined with naltrexone.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Intramural Research (Z01)
Project #
1Z01DA000121-13
Application #
6827523
Study Section
(MDRB)
Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
2003
Total Cost
Indirect Cost
Name
National Institute on Drug Abuse
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Matyas, Gary R; Mayorov, Alexander V; Rice, Kenner C et al. (2013) Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs. Vaccine 31:2804-10
Pelotte, Andrea L; Smith, Ryan M; Ayestas, Mario et al. (2009) Design, synthesis, and characterization of 6beta-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes. Bioorg Med Chem Lett 19:2811-4
Xu, Heng; Wang, Xiaoying; Partilla, John S et al. (2008) Differential effects of opioid agonists on G protein expression in CHO cells expressing cloned human opioid receptors. Brain Res Bull 77:49-54
Prisinzano, Thomas E; Rothman, Richard B (2008) Salvinorin A analogs as probes in opioid pharmacology. Chem Rev 108:1732-43
Simpson, Denise S; Katavic, Peter L; Lozama, Anthony et al. (2007) Synthetic studies of neoclerodane diterpenes from Salvia divinorum: preparation and opioid receptor activity of salvinicin analogues. J Med Chem 50:3596-603
Cheng, Kejun; Kim, In Jong; Lee, Mei-Jing et al. (2007) Opioid ligands with mixed properties from substituted enantiomeric N-phenethyl-5-phenylmorphans. Synthesis of a micro-agonist delta-antagonist and delta-inverse agonists. Org Biomol Chem 5:1177-90
Hiebel, Anne-Cecile; Lee, Yong Sok; Bilsky, Edward et al. (2007) Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorph J Med Chem 50:3765-76
Rothman, Richard B; Murphy, Daniel L; Xu, Heng et al. (2007) Salvinorin A: allosteric interactions at the mu-opioid receptor. J Pharmacol Exp Ther 320:801-10
Groer, C E; Tidgewell, K; Moyer, R A et al. (2007) An opioid agonist that does not induce micro-opioid receptor--arrestin interactions or receptor internalization. Mol Pharmacol 71:549-57
Xu, Heng; Partilla, John S; Wang, Xiaoying et al. (2007) A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependence. Synapse 61:166-75

Showing the most recent 10 out of 47 publications